|
|
|
|
| Market Access |
 |
|
NASH: Still Waiting |
Sabina Heinz and Elizabeth Baynton look at how the continued absence of approved products are affecting the management of nonalcoholic steatohepatitis (NASH) patients
… /Read more/ |
|
|
|
| Strategy |
 |
|
Making the Most of Maturing Oncology Brands |
A checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there's hidden vitality still left in their aging brands
… /Read more/ |
|
|
|
| US |
 |
|
|
|
| Industry update |
| //
Biopharma veteran Edwina Baskin-Bey, M.D., joined Nanobiotix (Paris, France and Cambridge, MA) as Chief Medical Officer.
//
Avadel Pharmaceuticals (Dublin, Ireland) announced the appointment of Gregory J. Divis as Chief Executive Officer and member of the Board of Directors. Mr. Divis has served as Interim CEO since January 2019.
//
Immuno-oncology company Immodulon (Uxbridge, UK) appointed Thomas O. Kleen, Ph.D., as Chief Scientific Officer.
//
Mundipharma (Cambridge, UK) appointed Jerome Moreau as Head of Market Access.
//
BioPorto (Hellerup, Denmark) appointed Amy Winslow as President of its US subsidiary, BioPorto Diagnostics, Inc.
|
|
|
|
|
|
|
|
|
